Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Viruses ; 13(6)2021 06 08.
Article in English | MEDLINE | ID: mdl-34201179

ABSTRACT

Previous molecular characterization of Human immunodeficiency virus (HIV-1) samples from Cabo Verde pointed out a vast HIV-1 pol diversity, with several subtypes and recombinant forms, being 5.2% classified as AU-pol. Thus, the aim of the present study was to improve the characterization of these AU sequences. The genomic DNA of seven HIV-1 AU pol-infected individuals were submitted to four overlapping nested-PCR fragments aiming to compose the full-length HIV-1 genome. The final classification was based on phylogenetic trees that were generated using the maximum likelihood and bootscan analysis. The genetic distances were calculated using Mega 7.0 software. Complete genome amplification was possible for two samples, and partial genomes were obtained for the other five. These two samples grouped together with a high support value, in a separate branch from the other sub-subtypes A and CRF26_A5U. No recombination was verified at bootscan, leading to the classification of a new sub-subtype A. The intragroup genetic distance from the new sub-subtype A at a complete genome was 5.2%, and the intergroup genetic varied from 8.1% to 19.0% in the analyzed fragments. Our study describes a new HIV-1 sub-subtype A and highlights the importance of continued molecular surveillance studies, mainly in countries with high HIV molecular diversity.


Subject(s)
Genetic Variation , Genotype , HIV Infections/epidemiology , HIV Infections/virology , HIV-1/classification , HIV-1/genetics , Adult , Cabo Verde , Evolution, Molecular , Female , Genome, Viral , Humans , Male , Middle Aged , Phylogeny , Public Health Surveillance , Young Adult , pol Gene Products, Human Immunodeficiency Virus/genetics
2.
AIDS ; 23(5): 641-3, 2009 Mar 13.
Article in English | MEDLINE | ID: mdl-19525622

ABSTRACT

Several case reports have demonstrated that the immune reconstitution inflammatory syndrome induces reversal reaction in HIV and leprosy-coinfected patients. The present study describes 10 cases of immune reconstitution inflammatory-associated reversal reaction. The patients evolved satisfactorily despite presenting a more severe form of the disease and the fact that three required an additional use of corticoids. The present study, the largest case series published to date, demonstrates that leprosy reaction is a manifestation of immune reconstitution.


Subject(s)
Immune Reconstitution Inflammatory Syndrome/complications , Leprosy/complications , Adult , Antiretroviral Therapy, Highly Active , Cohort Studies , Female , HIV Infections/complications , HIV Infections/drug therapy , HIV Infections/immunology , Humans , Immune Reconstitution Inflammatory Syndrome/immunology , Leprosy/immunology , Male , Middle Aged , Young Adult
3.
Clin Drug Investig ; 26(8): 469-79, 2006.
Article in English | MEDLINE | ID: mdl-17163279

ABSTRACT

OBJECTIVE: To assess the drug concentrations, efficacy and safety of concomitant use of rifampicin and regimens containing ritonavir/saquinavir (400mg/400mg twice daily) in tuberculosis-HIV treatment-naive patients. DESIGN AND METHODS: This was an open-label, non-randomised, multiple-dose study. On study day (D)1, tuberculosis treatment (rifampicin 600mg/isoniazid 400mg per day fasting plus pyrazinamide 2 g/day) was introduced in 30 patients. On D31, highly active antiretroviral therapy (HAART) consisting of two nucleoside analogues plus ritonavir/saquinavir 400mg/400mg twice daily was initiated (n = 20). The pharmacokinetics were assayed with a validated reversed-phase HPLC method before the introduction of HAART on D30 (for rifampicin), after 30 days of HAART at D60 (for rifampicin plus ritonavir/saquinavir), and at the end of the study (without rifampicin) on D210 (for ritonavir/saquinavir). Clinical evaluations were performed on a monthly basis. CD4 counts and viral load were collected on D30, D60 and D180. Genotyping test for HIV was collected at baseline and at D180. Primary endpoints were drug concentration and viral load at D180 (<80 copies/mL). Secondary endpoints were presence of grade 3 and serious adverse events, clinical improvement, CD4 count and genotypic resistance to ritonavir/saquinavir. RESULTS: Ten patients dropped out of the study during tuberculosis therapy alone. Mean (+/- SD) baseline CD4 count (on D30) was 151.89 (+/- 146.77) cells/mm(3) and viral load was 5.34 (+/- 0.4) log. During the antiretroviral therapy, 15 patients dropped out, 14 because of adverse events. One patient (of five) presented a viral load of <80 copies/mL at D180. All but one patient increased CD4 counts from baseline. No genotypic resistance was detected. Clinical improvement was evident in all five patients who tolerated the therapy. Serum concentrations of ritonavir/saquinavir and rifampicin remained within the therapeutic range. CONCLUSIONS: Therapeutic concentrations of the studied drugs and reduction of viral load were achieved; adverse events are the main limitation of use of a ritonavir/saquinavir regimen in treatment-naive patients, but its clinical benefits were evident.


Subject(s)
HIV Infections/drug therapy , Rifampin/therapeutic use , Ritonavir/therapeutic use , Saquinavir/therapeutic use , Tuberculosis/drug therapy , AIDS-Related Opportunistic Infections/complications , AIDS-Related Opportunistic Infections/drug therapy , Adult , Antibiotics, Antitubercular/adverse effects , Antibiotics, Antitubercular/pharmacokinetics , Antibiotics, Antitubercular/therapeutic use , Antiretroviral Therapy, Highly Active/methods , Area Under Curve , Bisexuality/statistics & numerical data , CD4 Lymphocyte Count , Drug Administration Schedule , Female , HIV Infections/complications , HIV Protease Inhibitors/adverse effects , HIV Protease Inhibitors/pharmacokinetics , HIV Protease Inhibitors/therapeutic use , Half-Life , Homosexuality/statistics & numerical data , Humans , Karnofsky Performance Status , Male , Metabolic Clearance Rate , Rifampin/adverse effects , Rifampin/pharmacokinetics , Ritonavir/adverse effects , Ritonavir/pharmacokinetics , Saquinavir/adverse effects , Saquinavir/pharmacokinetics , Time Factors , Treatment Outcome , Tuberculosis/complications , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL
...